Cancer Research Breakthrough: The National Foundation for Cancer Research (NFCR) Cites Manhattan Scientifics' Early Cancer Detection Technology as "Research Breakthrough" for 2012

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--

The National Foundation for Cancer Research (NFCR) has listed the SQUID-based cancer imaging technology developed by MHTX's MHTX Senior Scientific subsidiary as a “2012 Research Breakthrough.” http://nfcr.org/research/research-accomplishments. The technology was developed by Edward R. Flynn, PhD, Senior Scientific's founder and chief scientist, in collaboration with Richard S. Larson, MD, PhD, Executive Vice Chancellor UNM Health Sciences Center in New Mexico.

The NFCR has supported Dr. Robert C. Bast, Jr. of The University of Texas MD Anderson Cancer Center to collaborate with Senior Scientific in applying Senior Scientific's technology to the early detection of ovarian cancer. The collaboration was previously press released at http://www.mhtx.com/press-releases/national-foundation-funds-novel-approach-to-early-cancer-detection/. Dr. Bast is a world leader in the early detection of ovarian cancer. He was responsible for the discovery of the most accurate marker for this disease, CA-125. Dr. Bast and Senior Scientific are working to apply the SQUID-based imaging technology to help save many women's lives from ovarian cancer - the notorious "silent killer" which often escapes early detection and becomes too difficult to treat when eventually diagnosed.

The technology uses Superconducting Quantum Interference Devices (SQUIDs) and non-toxic iron oxide nanoparticles to find and measure cancer and to develop new biomarkers for targeting specific cancers. It is expected to be able to detect cancer years earlier than existing techniques as well as find cancers not detectable by current methods through these new biomarkers. The technology is applicable to many cancers and has been demonstrated in application to ovarian cancer, breast cancer, prostate cancer and leukemia.

About Manhattan Scientifics

Manhattan Scientifics Inc. (www.mhtx.com), located in New Mexico, New York and Montreal, is focused on technology transfer and commercialization of disruptive technologies in the nano-medicine space. It has achieved several critical milestones in the development of its proprietary technology for the early detection and treatment of cancer. The company also is diligently working with its commercial partners to build super-strength metals and alloys to make extremely light weight products. The company is developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano-medical applications developed by Senior Scientific LLC, a unit of the company.

About Senior Scientific

Senior Scientific, LLC (www.seniorscientific.com) is a New Mexico Company with research facilities located at the University of New Mexico Science and Technology Park in Albuquerque, New Mexico and longstanding relationships with the University of New Mexico Health Sciences Center, and the Center for Integrated Nanotechnology (CINT) at Sandia National Laboratory. The Company's focus is in the emerging field of molecular imaging and nanobiotechnology for the early detection and localization of cancer and other human diseases, and is the leader in a technology called Nanomagnetic Relaxometry (“NMR”). Its proprietary technologies and methods employ magnetic nanoparticles targeted towards cells associated with cancer and other diseases, and detect those cells tagged with magnetic nanoparticles through sophisticated magnetic sensors.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.